RATIONALE: Polygala sabulosa, a folk medicine, presents dihydrostyryl-2-pyrones (DST) and styryl-2-pyrones (STY), compounds structurally similar to kavalactones. Our previous study showed that the ethyl acetate fraction (EA) and these constituents present anxiolytic-like, hypno-sedative, and anticonvulsant effects in mice. OBJECTIVES: This study investigated the role of benzodiazepine binding site (BDZ-bs) in the central effects of either EA or three DST (1, 2, and 3) and three STY (4, 5, and 7), using in vivo and in vitro assays. METHODS AND RESULTS: In the elevated plus-maze (EPM), flumazenil (FMZ), a BDZ antagonist, partially blocked the anxiolytic-like effect of DST-3 or STY-4 and STY-7, but not DST-1. Using electroencephalogram (EEG), EA protected against pentylenetetrazole (PTZ)-induced convulsion in rats, an effect partially blocked by FMZ, suggesting the participation of the BDZ-bs in this action. EA also protected against the maximal electroshock (MES)-induced convulsions in mice, a profile distinct from diazepam (DZP). DST and STY compounds inhibited the [(3)H]-flunitrazepam ([(3)H]-FNZ) binding to BDZ-bs in rat cortical synaptosomes with K (i) higher than 100 microM (DST-1), 41.7 microM (DST-2), 35.8 microM (DST-3), 90.3 microM (STY-4), 31.0 microM (STY-5) and 70.0 microM (STY-7). In the saturation assay, DST-3 and STY-7 competitively inhibited the binding of [(3)H]-FNZ to BDZ-bs with a significant decrease in apparent affinity (K (d)) and no change in maximal binding (B (max)). CONCLUSIONS: The present data support a partial BDZ-bs mediation of the anxiolytic-like and anticonvulsant effects of EA of P. sabulosa and its main isolated constituents, DST and STY.
RATIONALE: Polygala sabulosa, a folk medicine, presents dihydrostyryl-2-pyrones (DST) and styryl-2-pyrones (STY), compounds structurally similar to kavalactones. Our previous study showed that the ethyl acetate fraction (EA) and these constituents present anxiolytic-like, hypno-sedative, and anticonvulsant effects in mice. OBJECTIVES: This study investigated the role of benzodiazepine binding site (BDZ-bs) in the central effects of either EA or three DST (1, 2, and 3) and three STY (4, 5, and 7), using in vivo and in vitro assays. METHODS AND RESULTS: In the elevated plus-maze (EPM), flumazenil (FMZ), a BDZ antagonist, partially blocked the anxiolytic-like effect of DST-3 or STY-4 and STY-7, but not DST-1. Using electroencephalogram (EEG), EA protected against pentylenetetrazole (PTZ)-induced convulsion in rats, an effect partially blocked by FMZ, suggesting the participation of the BDZ-bs in this action. EA also protected against the maximal electroshock (MES)-induced convulsions in mice, a profile distinct from diazepam (DZP). DST and STY compounds inhibited the [(3)H]-flunitrazepam ([(3)H]-FNZ) binding to BDZ-bs in rat cortical synaptosomes with K (i) higher than 100 microM (DST-1), 41.7 microM (DST-2), 35.8 microM (DST-3), 90.3 microM (STY-4), 31.0 microM (STY-5) and 70.0 microM (STY-7). In the saturation assay, DST-3 and STY-7 competitively inhibited the binding of [(3)H]-FNZ to BDZ-bs with a significant decrease in apparent affinity (K (d)) and no change in maximal binding (B (max)). CONCLUSIONS: The present data support a partial BDZ-bs mediation of the anxiolytic-like and anticonvulsant effects of EA of P. sabulosa and its main isolated constituents, DST and STY.
Authors: Kathryn R Starr; Gary W Price; Jeannette M Watson; Peter J Atkinson; Roberto Arban; Sergio Melotto; Lee A Dawson; Jim J Hagan; Neil Upton; Mark S Duxon Journal: Neuropsychopharmacology Date: 2007-03-14 Impact factor: 7.853
Authors: Filipe S Duarte; Marcelo Duzzioni; Alexandre A Hoeller; Nayana M Silva; Andy L Ern; Tetsade C Piermartiri; Carla I Tasca; Elaine C Gavioli; Tadeu Lemos; Antonio P Carobrez; Thereza C M De Lima Journal: Psychopharmacology (Berl) Date: 2012-12-29 Impact factor: 4.530
Authors: Cristina Martins-Silva; Natalie de Souza Pinho; Glenda G Ferreira; Rafael Moraes Aguiar; Tamara Alarcon Ferreira; Rita G W Pires; Tiago Tizziani; Moacir G Pizzolatti; Adair R S Santos Journal: Metab Brain Dis Date: 2021-01-04 Impact factor: 3.584
Authors: Mark A Smith; Jordan C Iordanou; Marika B Cohen; Kathryn T Cole; Samantha R Gergans; Megan A Lyle; Karl T Schmidt Journal: Behav Pharmacol Date: 2009-07 Impact factor: 2.293
Authors: Filipe Silveira Duarte; Marcelo Duzzioni; Rafael Luiz Prim; Alcíbia Maia Cardozo; Claudia Regina Dos Santos; Maria Goretti da Silva; Maria Beatriz Cacese Shiozawa; Beatriz Garcia Mendes; Tiago Tizziani; Inês Maria Costa Brighente; Moacir Geraldo Pizzolatti; Thereza Christina Monteiro de Lima Journal: J Pharm Pharmacol Date: 2018-06-28 Impact factor: 3.765
Authors: Susana Johann; Beatriz G Mendes; Fabiana C Missau; Maria A de Resende; Moacir G Pizzolatti Journal: Braz J Microbiol Date: 2011-09-01 Impact factor: 2.476